Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

141.10 2.33 +1.68%
Market cap
$9.6B
P/E
26.4×
Fwd P/E
24.7×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
81.21 43.66 70.88 4,091.14 1,156.83 2,323.91 951.11 1,322.00 0.00 0.00
Piotroski F-Score
6 8 6 4 4 5 5 6 5 6
P/S ratio
7.38 8.83 8.59 15.22 16.39 18.30 14.05 8.28 8.63 5.83
Altman Z-Score
9.09 7.40 6.15 7.68 8.18 8.56 6.26 4.03 3.64 2.76
P/FCF ratio
57.15 61.76 399.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
4.78 4.29 3.38 2.31 3.30 3.17 0.94 0.55 0.99 (0.33)
Beneish M-Score
(2.59) (2.35) (1.85) (2.18) (1.72) (2.49) (3.07) (2.17) (1.56) (3.23)
P/Operating CF
109.09 124.03 322.69 391.87 (706.37) 973.42 221.19 153.38 182.81 106.54
P/B ratio
13.20 15.10 19.91 41.70 32.38 27.42 136.68 22.01 25.25 33.86
Price to Tangible BV
14.85 17.23 25.05 56.89 37.53 30.93 453.00 28.80 35.01 99.77
EV/Sales
7.47 9.04 9.01 15.78 16.83 18.42 14.75 8.86 8.95 5.98
EV/EBITDA
35.85 48.04 52.23 204.31 100.84 155.85 139.79 116.18 638.80 701.95
EV/Operating CF
35.53 43.52 104.99 173.06 (271.58) 198.33 110.67 139.16 100.54 138.04
EV/FCF
57.81 63.20 419.10 (537.72) (96.93) (201.94) (150.20) (38.46) (127.76) (354.03)
Quick Ratio
1.81 2.50 2.36 2.41 4.16 5.02 2.82 3.16 5.74 5.88
Current Ratio
2.81 3.58 3.51 3.60 5.81 6.01 3.75 3.99 6.24 6.64
Net Debt/EBITDA
0.41 1.09 2.43 7.21 2.63 1.04 6.62 7.05 19.40 10.93
Debt/Assets
29.75% 44.69% 54.70% 62.27% 62.18% 56.56% 78.04% 63.75% 69.32% 72.87%
Debt/Equity
0.63 1.14 1.93 2.94 2.29 1.76 11.75 2.79 3.57 5.27
Asset Turnover
0.86 0.73 0.70 0.61 0.56 0.60 0.71 0.65 0.73 1.00
Operating CF/Net income
2.30 1.03 0.71 25.87 (4.05) 12.35 8.48 10.88 (1.54) (0.55)
Capex/Depreciation
(2.43) (1.66) (1.50) (2.49) (2.14) (3.01) (6.13) (10.41) (5.55) (1.60)
Interest Coverage
7.98 7.23 6.08 1.04 2.04 1.14 1.81 1.29 (0.35) (0.74)
ROE
18.12% 43.03% 34.12% 0.89% 2.90% 2.00% 8.06% 1.78% (24.18%) (59.42%)
ROA
7.87% 14.74% 8.53% 0.21% 0.86% 0.45% 1.12% 0.38% (4.21%) (7.89%)
ROIC
16.94% 11.79% 9.52% 1.95% 7.58% 4.50% 5.28% 3.32% (1.62%) (6.87%)
Return on Tangible Assets
12.03% 20.05% 11.48% 0.30% 1.03% 0.45% 1.39% 0.55% (4.79%) (8.04%)
Average Days of Receivables
69.67 64.40 77.36 57.49 53.48 38.46 34.27 49.66 42.00 28.65
Research and Development Expense of Revenue
11.12% 10.60% 12.08% 13.81% 14.57% 16.23% 17.92% 15.79% 16.32% 15.18%
Selling, General and Administrative Expense of Revenue
43.02% 44.27% 43.30% 45.03% 42.41% 42.46% 40.37% 43.99% 45.04% 45.25%
Intangible Assets out of Total Assets
0.05 0.05 0.06 0.06 0.04 0.04 0.05 0.05 0.05 0.09
Share Based Compensation of Revenue
2.32% 3.35% 2.85% 3.13% 3.13% 3.97% 3.89% 6.65% 6.88% 6.44%
Graham Net Nets
0.01 0.00 (0.02) (0.02) (0.01) 0.00 (0.05) (0.05) (0.03) (0.01)
Graham Number
41.19 48.23 26.41 3.29 6.52 4.80 2.25 2.21 0.00 0.00
Earnings Yield
1.23% 2.29% 1.41% 0.02% 0.09% 0.04% 0.11% 0.08% (0.67%) (1.37%)
Free Cash Flow Yield
1.75% 1.62% 0.25% (0.19%) (1.06%) (0.50%) (0.70%) (2.78%) (0.81%) (0.29%)
Revenue per Share
38.50 29.56 24.33 18.82 16.23 13.97 12.18 9.58 8.00 6.41
Operating CF per Share
8.09 6.14 2.09 1.72 (1.01) 1.30 1.62 0.61 0.71 0.28
Capex per Share
(3.12) (1.91) (1.57) (2.27) (1.81) (2.57) (2.82) (2.76) (1.33) (0.39)
Free Cash Flow per Share
4.97 4.23 0.52 (0.55) (2.82) (1.27) (1.20) (2.15) (0.62) (0.11)
Cash per Share
10.18 13.61 10.10 9.73 11.69 14.64 6.21 4.91 7.59 5.22
Shareholders Equity per Share
21.54 17.29 10.50 6.87 8.22 9.32 1.25 3.60 2.73 1.10
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
21.54 17.29 10.50 6.87 8.22 9.32 1.25 3.60 2.73 1.10
Free Cash Flow
349.90 296.20 36.50 (38.30) (190.80) (82.50) (72.50) (126.50) (35.90) (6.20)
Working Capital
1,233.90 1,362.90 1,131.70 949.30 1,101.00 1,040.90 433.30 345.60 451.15 314.26
Capital Expenditures
(219.40) (134.00) (109.20) (157.30) (122.70) (166.50) (170.90) (162.40) (77.20) (22.11)
Net Current Asset Value
238.80 15.20 (272.60) (460.70) (162.70) (20.60) (476.00) (255.30) (121.06) (23.54)
EV/EBIT
42.69 60.61 69.50 547.73 146.78 323.49 217.79 187.68 0.00 0.00
Capex to Sales
0.08 0.06 0.06 0.12 0.11 0.18 0.23 0.29 0.17 0.06
Price to Operating Income
42.20 59.23 66.27 528.39 142.96 321.32 207.47 175.39 0.00 0.00
Other line items
Depreciation/Fixed assets
0.11 0.11 0.11 0.11 0.11 0.12 0.07 0.06 0.13 0.31
Cash ROIC
11.00% 8.36% 1.28% (1.50%) (7.28%) (3.16%) (5.39%) (11.57%) (3.08%) (0.89%)
Accounts Receivable Turnover
6.14 5.71 6.00 7.12 8.57 10.99 10.11 8.67 11.29 10.29
Accounts Payable Turnover
16.21 32.10 21.49 14.59 7.55 5.93 6.45 7.76 9.93 10.99
Inventory Turnover
1.74 1.50 1.43 1.54 1.52 2.52 2.99 3.68 5.38 6.56
Average Days of Payables
35.64 11.55 13.05 22.50 39.69 61.31 77.13 48.08 47.75 30.81
Days of Inventory on Hand
215.05 250.99 273.55 253.32 319.20 174.85 142.94 134.61 66.10 83.15
Average Receivables
441.20 362.60 282.65 183.30 128.15 82.30 73.00 65.04 41.09 35.67
Average Payables
47.40 19.50 25.00 34.25 45.90 54.30 40.00 24.96 18.79 14.19
Average Inventory
441.50 416.50 374.70 325.00 228.75 127.65 86.20 52.60 34.65 23.77
Average Assets
3,139.05 2,837.95 2,419.65 2,149.95 1,960.85 1,507.90 1,035.80 872.72 636.70 365.89
Average Common Equity
1,363.45 972.15 604.55 516.35 579.95 339.75 144.00 185.31 110.83 48.60

Fold the line items

Columns are period end dates